Funding

InduPro

United States · Biotech

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

Visit induprotx.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series B$77MEli Lilly and Company — Role not disclosedEmerson Collective — Role not disclosedEuclidean Capital — Role not disclosedMRL Ventures Fund — Role not disclosedSanofi — Role not disclosedSolasta Ventures — Role not disclosedThe Column Group — Role not disclosedVida Ventures — Role not disclosed

Investors

Eli Lilly and CompanySeries BEmerson CollectiveSeries BEuclidean CapitalSeries BMRL Ventures FundSeries BSanofiSeries BSolasta VenturesSeries BThe Column GroupSeries BVida VenturesSeries B

Coverage

Aug 12, 2026InduPro · Series B

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesinduprotx.com ↗